Surface Oncology has dosed the first patient in its Phase I trial evaluating the safety and tolerability of SRF231 in patients with advanced solid tumours and hematologic malignancies.

In the trial SRF231 will be given in multiple ascending doses to the enrolled patients, with an aim to establish a recommended dose for further study.

“Targeting the tumour microenvironment has tremendous therapeutic potential.”

After completing the dose escalation component of the trial, Surface plans to analyse the safety and efficacy of SRF231 in cohorts of patients with specific types of cancer.

South Texas Accelerated Research Therapeutics Clinical Research associate director and trial investigator Amita Patnaik said: “Targeting the tumour microenvironment has tremendous therapeutic potential.

“Our team is eager to evaluate the role of macrophage activation through SRF231 to expand the opportunities for patients with cancer to benefit from immunotherapy.”

SRF231 is a human antibody that prevents the activity of CD47, a protein over-expressed on various types of cancer cells that prevents them from being eliminated by macrophages.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Findings from preclinical studies have showed that SRF231 has potent anti-tumour activity both preclinically in different tumour models and in combination with existing cancer modalities.

The studies have also demonstrated that SRF231 does not induce hemagglutination, an important potential safety advantage.

Development of SRF231 is supported by a strategic collaboration between Surface and Novartis, under which the former has the option to retain the development and commercial rights of the drug in the US.